Skip to content
Screener

R&D at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$258M-13.1%
Sanara MedTech Inc. logo
Sanara MedTech Inc.SMTI
$759.59K-20.1%
DENTSPLY SIRONA logo
DENTSPLY SIRONAXRAY
$45M+21.6%
Align Technology logo
Align TechnologyALGN
$102.03M+5.8%
Oracle logo
OracleORCL
$2.61B-1.5%
SANUWAVE Health, Inc. logo
SANUWAVE Health, Inc.SNWV
$628K+224%

Other financials

Income statement

See full
Revenue$2.2B+2.2%
Gross profit$1.3B+9.4%
Operating income$181.0M-15.4%
Net income$92.0M+2.2%
EPS (diluted)$0.53+3.9%

Balance sheet

See full
Cash & equivalents$403.0M-18.1%
Total debt$5.8B-25.9%
Total equity$4.8B+31.7%
Total assets$14.2B-5.5%

Cash flow

See full
Operating cash flow$227.0M+34.3%
CapEx$83.0M-24.5%
Free cash flow-$273.0M-241%

Valuation

See full
Market cap$15.15B+20.6%
Enterprise value$20.54B+3.3%
P/E10.6×-22.5×
P/S1.8×+0.3×

Profitability

See full
Gross margin54.7%+0.2pp
Operating margin25%+15.7pp
Net margin17.3%+12.7pp
FCF margin4.6%-13.9pp

Returns & leverage

See full
Return on equity34%+22.3pp
Debt / equity1.2×-0.9×
Current ratio-0.2×

Where this comes from

Reported directly by Solventum in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Solventum’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:27 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001964738-26-000047
(Millions, except per share data)Three months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Cost of software and rentals116121231242
Gross profit1,2861,1752,3822,289
Selling, general and administrative expenses9277721,7541,541
Research and development expenses178189367381
Operating income181214262367
Interest expense, net64103125207
Other expense (income), net981319
Income before income taxes108103123141

Item 1. Financial Statements

FAQ

What is Solventum's R&D?
Solventum (SOLV) reported R&D of $178M in Q2 2026.
How has Solventum's R&D changed year-over-year?
Solventum's R&D decreased by 5.8% year-over-year, from $189M to $178M.
What is the long-term trend for Solventum's R&D?
Over 3 years (2022 to 2025), Solventum's R&D has grown at a -1.2% compound annual growth rate (CAGR), from $767M to $740M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Ask your AI about Solventum's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude